心臓のフォスホイノシチド3キナーゼp110αの喪失は,収縮性機能不全を引き起こす
Zhongju Lu1, Ya-Ping Jiang, Wei Wang
1Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY 11794-8151, USA.
Circulation
|July 15, 2009
まとめ
フォスフォノシチド3キナーゼ (PI3K) p110alphaは,L型カルシウムチャネル (LTCC) を制御することによって,心臓の収縮性を調節する. p110alphaの損失は,LTCCを減少させ,心臓の機能を低下させます.
科学分野:
- 心血管生理学 心血管の生理学
- 分子生物学は分子生物学である.
- 細胞シグナル伝達 細胞信号伝達
背景:
- フォスフォノシチド3キナーゼ (PI3K) p110alphaは,インスリン作用と癌に不可欠です.
- 筋細胞の収縮は,L型カルシウムチャネル (LTCC) を通したL型カルシウム電流 (I(Ca,L)) に依存する.
研究 の 目的:
- PI3K p110alphaが,LTCCsを調節することによって心臓の収縮性を調節するかどうかを調査する.
主な方法:
- p110alphaとp110betaの遺伝的アブレーションが,大人のマウスの心筋細胞に起こりました.
- 犬のミオサイトにおけるp110alphaおよびp110betaの薬理学的抑制.
- I ((Ca,L) の測定,LTCCの表面表現,および心臓機能.
主要な成果:
- マウスではp110alpha,p110betaではなくp110alphaの遺伝的消去により,I(Ca,L) が低下し,心臓インスリンシグナル伝達が阻害される.
- p110alpha-nullミオサイトは,細胞表面に LTCC が少なく,収縮性欠陥と in vivo 心臓機能の低下を引き起こしました.
- p110alphaの薬理学的抑制は,p110betaではないが,犬のミオサイトのI (Ca,L) と収縮性を低下させた.
結論:
- PI3K p110alphaは,p110betaではないが,心筋細胞におけるLTCCの主要な調節体である.
- 減少したp110αシグナリングは,細胞表面のLTCCを減少させ,I(Ca,L) と心臓の収縮性を弱める.
関連する概念動画
Pathophysiology of Heart Failure
5.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
5.1K
Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Myocarditis I: Introduction
647
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
647
Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810


